Chuandong Geng
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, PARP inhibition in cancer therapy, Cancer, Lipids, and Metabolism, Estrogen and related hormone effects, Advanced Breast Cancer Therapies
Most-Cited Works
- → Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover(2013)254 cited
- → Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer(2014)195 cited
- → ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer(2021)139 cited
- → GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex(2014)127 cited
- → PARP Inhibition Suppresses GR–MYCN–CDK5–RB1–E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer(2019)73 cited
- → PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer(2021)56 cited
- → miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation(2015)40 cited
- → Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells(2014)11 cited
- → Correction: Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer(2019)4 cited
- → DNA Damage Response Inhibitor and Anti-PD-L1 Therapy for Prostate Cancer: Development of Predictive Biomarkers(2022)1 cited